TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01735682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control treatment involves exercises of the upper limbs.
Study: NCT00272948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
Study: NCT01477606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)
Study: NCT00710710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion
Study: NCT01365325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: handled echocardiography in home monitoring program
Description: home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
Study: NCT00272948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
Study: NCT03978962

Intervention type: DEVICE
Intervention: Guided Tissue Regeneration
Description: Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction.
Study: NCT01365325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ecg and clinical evaluation in home monitoring program
Description: home monitoring with clinical evaluations and ECG every three months
Study: NCT03045328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
Study: NCT04359732

Intervention type: OTHER
Group type: OTHER
Intervention: hybrid PET/MRI
Description: An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
Study: NCT03292939

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: A complete Doppler ﬂow assessment of the maternal and fetal circulation
Description: A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
Study: NCT02165956

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Infant Cereal
Description: New Infant Cereal

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Cereal
Description: Standard Infant Cereal
Study: NCT02973542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
Study: NCT04052438

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.

Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.
Study: NCT04553653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: checklist
Description: The checklist will be implemented and healthcare providers use the checklist to manage the patients.
Study: NCT00280800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: constant CPAP devices
Description: different CPAP mode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic CPAP devices
Description: different CPAP mode
Study: NCT01806025

Intervention type: OTHER
Intervention: no intervention
Study: NCT01166958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
Study: NCT04690803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: air cooling
Description: intervention is adding air-cooling to treatment
Study: NCT04503668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg IV on day 1 pre-chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV on day 1 pre-chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurokinin-1 Receptor Antagonist (NK1-RA)
Description: 150 mg IV on day 1 pre-chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 mg by mouth on days 1-4 of chemotherapy (taken at night)
Study: NCT04378413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise for low back pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise for low back pain
Study: NCT02599324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
Study: NCT04503668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine
Description: 5-10 mg by mouth, available as needed, every 6 hours, days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compazine
Description: 5-10 mg by mouth, available as needed, every 6 hours, days 1-5
Study: NCT02599324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
Study: NCT02813668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Training Program
Description: Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
Study: NCT04393467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: tSMS delivered on bilateral motor cortex
Study: NCT02599324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
Study: NCT03485404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylcobalamin
Description: methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: folic acid tablets, 5mg/tablet, 1 tablet/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for methylcobalamin
Description: orange tablets that looks exactly like methylcobalamin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for folic acid
Description: yellow tablets that looks exactly like folic acid

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non-cardiac surgery
Description: patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-cardiac surgery
Description: patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
Study: NCT04383665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS 10Hz
Description: Stimulation of existing DBS device at 100Hz, with other parameters at baseline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STN DBS 130Hz
Description: Stimulation of existing DBS device at 130Hz, with other parameters at baseline

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STN DBS off
Description: Existing DBS device turned off
Study: NCT00671190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally once daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 2 mg, tablets, orally once daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally once daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally once daily for up to 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally once daily for up to 5 days
Study: NCT04453618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE-SYHA1402 100mg
Description: in either a fasted state or with a meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-25mg
Description: SYHA1402 25mg, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-25mg
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-50mg
Description: SYHA1402 50mg, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-50mg
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-150mg
Description: SYHA1402 150mg, oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-150mg
Description: Matching placebo tablets
Study: NCT02685449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glulisine
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study: NCT00957060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE (HOE490)
Description: Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SITAGLIPTIN
Description: Pharmaceutical form: 100 mg tablets Route of administration: oral
Study: NCT01308528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin
Description: 40 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Enoxaparin clexane
Description: clexane 40 mg/ 0,4 mL
Study: NCT02477540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellgram-CLI
Description: Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular
Study: NCT03530189

Intervention type: DRUG
Intervention: 10% dextrose
Description: After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible

Intervention type: DRUG
Intervention: bolus of dextrose, reducing the glucose infusion, insulin
Description: Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
Study: NCT01156012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2345
Description: One drop of T2345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin
Description: One drop
Study: NCT01662128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda as Adjuvant Therapy
Study: NCT01562379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Soy Blend (WSB++)
Description: A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea based complementary food supplement
Description: A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
Study: NCT04393467

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tSMS
Description: sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
Study: NCT05034315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole egg consumption
Description: The participants in the whole egg group consumed two whole eggs immediately after exercise.
Study: NCT04151628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Description: Deliver Lithotripsy to the target vessel prior to placing a coronary stent
Study: NCT04362371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ainara
Description: 1 g at each administration
Study: NCT01294943

Intervention type: DEVICE
Intervention: Tongue cleaner
Description: Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
Study: NCT00353431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid ®, Novo Nordisk, Denmark
Description: Comparison of a sliding scale with an intensive s.c. scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novorapid ®, Novo Nordisk, Denmark
Description: Comparison of a sliding scale with an intensive s.c. scale
Study: NCT04287569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Record during endoscopy of video-endoscopy sequences and reflectance
Description: Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
Study: NCT03271073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
Study: NCT04618042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX06
Description: FX06 i.v.: 400 mg per day (divided in two injections) during 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of FX06
Description: Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
Study: NCT03661788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 14-day treatment interval: first week one placebo pill, second week two placebo pills

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 14-day treatment interval: first week one placebo pill, second week two placebo pills
Study: NCT01866423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orteronel
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03252093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Subcutaneous injection of 200 mcg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Angiotensin-(1-7)
Description: Subcutaneous injection of Placebo